New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2013
16:15 EDTIDRAIdera announces presentation of data supporting results from IMO-3100 trial
Idera Pharmaceuticals announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis. The data presented by Dr. Krueger provide scientific support for the top-line results from the proof of concept Phase 2 trial of IMO-3100 in patients with psoriasis that Idera announced late last year. We look forward to presenting detailed results from the clinical trial at the International Investigative Dermatology Annual Meeting in May 2013,” commented Robert Arbeit, M.D., VP of Clinical Development at Idera. “In addition, during the first quarter, we completed the single dose portion of a Phase 1 clinical trial of IMO-8400 in healthy subjects. IMO-8400 was well-tolerated and demonstrated target engagement of TLRs 7, 8 and 9. The multiple-dose portion of the IMO-8400 Phase 1 trial is ongoing, and we anticipate data during the second quarter of 2013.”
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
07:37 EDTIDRAStifel to hold a conference
Subscribe for More Information
November 7, 2014
07:19 EDTIDRAIdera Pharmaceuticals to expand rare disease development portfolio
Idera Pharmaceuticals announced plans to collaborate with Parent Project Muscular Dystrophy, or PPMD, to develop a potential non-steroid-based anti-inflammatory treatment using Idera's Toll-like receptor, or TLR, antagonism technology. DMD is a rare, fatal muscle disorder affecting approximately 15,000-20,000 patients in the U.S. It is characterized by progressive muscle weakness, pulmonary and cardiac dysfunction, and death typically before age 30. Previously published independent research has shown that TLR 7 is up-regulated in DMD patients.1 In a preclinical model of DMD, knockout of the gene for the MYD88 TLR adaptor protein led to significant improvements in skeletal and cardiac muscle function. In a separate study conducted by researchers from Children's National Health System and Idera, treatment with a TLR antagonist candidate led to a significant reduction of pro-inflammatory cytokines, a significant decrease in creatine kinase, and a significant increase in muscle strength in a preclinical DMD model.2 Idera plans to collaborate with PPMD to expand preclinical studies and develop a clinical development strategy for a TLR antagonist candidate in DMD.
07:15 EDTIDRAIdera Pharmaceuticals reports Q3 EPS (11c), consensus (11c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use